Vaccine Clinical Trials from an Industry Perspective

As GSK and through our heritage companies, we have a 150-year legacy of applying science to discover and develop new medicines, vaccines and consumer healthcare products . To carry on our success in finding new products, over 11,000 people work in our Pharmaceutical, Vaccines and Consumer Healthcare R&D organisations, in major research centres around the world. We have three global vaccine R&D hubs located in Belgium, Italy and the USA, researching vaccines against bacterial, viral and parasitic pathogens. Our vaccines R&D is centred on discovering and developing prophylactic and therapeutic vaccines to protect people against infectious diseases, cancers and chronic disorders. Every disease has its own characteristics, and developing a vaccine to protect against a specific disease requires a unique approach. Although every disease, infectious or not, will have its own challenges, our work to develop and introduce a new vaccine typically goes through several stages. There are more than 40 GSK vaccines in use around the world, and every one of them has been through the same rigorous process before making it to market. Our vaccines continued effectiveness is a testament to the many long hours - often years - spent in the lab by our scientists in R&D.